Comparing CLSK and VEEV is less a like-for-like matchup than a study in contrasting risk and reward. CleanSpark is a digital-infrastructure company transitioning from cryptocurrency mining into high-performance computing, while Veeva Systems is an established, profitable provider of cloud software to pharmaceutical and life-sciences companies. This comparison is most relevant for investors weighing a high-beta, catalyst-driven turnaround story against a steadier, fundamentally strong growth franchise. Understanding their differing business models, momentum, and risk profiles can help traders and longer-term investors assess where each name sits in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in their respective industries.
CLSK, or CleanSpark, is a Nevada-based company historically known for Bitcoin mining that is now repositioning itself as a developer of AI and high-performance computing (HPC) data centers. The strategic centerpiece is a 20-year infrastructure lease at its Sandersville, Georgia campus valued at roughly $6.6 billion in contracted revenue. Recent weeks, however, have been volatile for the shares. The stock has retreated sharply from its 52-week highs as sentiment was pressured by several factors: a Texas election outcome that raised questions about new data-center approvals, multiple analyst downgrades and price-target reductions, and quarterly results that showed revenue declining roughly 25% year over year with a substantial GAAP net loss driven in part by Bitcoin mark-to-market charges. From what I see, the execution risks here are substantial.
VEEV, or Veeva Systems, provides cloud-based software and data solutions that help life-sciences companies manage clinical, regulatory, and commercial workflows. Its core products include Vault (content and data management) and Vault CRM (customer relationship management). Recent market activity has been notably strong: the stock has climbed substantially over the past several months, supported by a run of earnings beats, resilient subscription growth, and its addition to the S&P 500 index. The company has also leaned into artificial intelligence, launching agent-based tools and announcing large customer commitments from major pharmaceutical firms. This combination of consistent profitability, double-digit revenue growth, and high-profile contract wins has reinforced positive sentiment toward the stock. I’m watching this closely as the AI angle adds another layer of support.
The contrast between CLSK and VEEV is most visible across business model, profitability, and risk. CLSK is capital-intensive and currently unprofitable on a GAAP basis, with a balance sheet carrying significant long-term debt raised to fund its data-center buildout. Its investment case hinges on executing a multi-year infrastructure transition, and its stock exhibits high beta and elevated short interest. VEEV, by contrast, is a cash-generative software business with a roughly 44% to 45% adjusted operating margin and a recurring subscription revenue base, backed by long-standing relationships with large life-sciences customers.
Growth drivers also differ. CLSK's upside is tied to power capacity, lease signings, and data-center delivery timelines, all of which carry execution risk. VEEV's growth is driven by software adoption, AI product expansion, and customer renewals, which are more predictable. On the risk side, CLSK is sensitive to Bitcoin prices, energy economics, and regulatory decisions around data centers, while VEEV faces risks around customer concentration and potential pricing pressure from large pharmaceutical buyers. Market sentiment reflects these gaps: VEEV has shown steadier upward momentum and lower volatility, whereas CLSK has experienced sharper drawdowns amid its transition.
Based on observable factors such as trend consistency, earnings stability, volatility, and the clarity of near-term catalysts, Tickeron's AI would likely favor VEEV over CLSK in the current environment. VEEV presents a more consistent trend profile, sustained profitability, and visible growth drivers in software and AI, which tend to score favorably in systematic, data-driven frameworks. CLSK's long-term data-center opportunity is meaningful, but its negative adjusted EBITDA, heavy debt load, and high volatility introduce greater uncertainty around timing and execution. Accordingly, the probabilistic edge appears to reside with VEEV for investors prioritizing stability and earnings consistency.
In my view, one useful way to supplement this kind of analysis is by looking at how Tickeron’s automated systems are currently positioned. The platform’s Trending AI Robots section highlights bots that show the strongest alignment with prevailing market conditions, covering a range of strategies and timeframes across thousands of tickers. Reviewing these can provide an additional data point when evaluating names like CLSK and VEEV without relying solely on discretionary judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 78 similar instances where the indicator turned negative. In 54 of the 78 cases, the stock moved further down in the following days. The odds of a decline are at 69%.
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 31 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
VEEV moved below its 50-day moving average on November 17, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +0.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in 179 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
VEEV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 133 of 210 cases where VEEV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. VEEV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.617) is normal, around the industry mean (4.523). VEEV has a moderately high P/E Ratio (48.989) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (1.248) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (12.739) is also within normal values, averaging (6.105).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry